Precision clot treatment for disabling minor stroke with large vessel blockage beyond time window
Treatments studied
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests a specialized clot-removal treatment for people who had a mild but disabling stroke up to 24 hours ago and have a large artery blockage in the brain. The goal is to see if this precision therapy can help reduce disability and improve recovery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You had a stroke that started between 4.5 and 24 hours ago.
- You have a mild stroke (NIH Stroke Scale score 2 to 5) but it causes disabling problems like vision loss, trouble speaking, weakness in an arm or leg, or inability to do daily tasks.
- Imaging shows a large blood vessel blockage in the front part of your brain.
- Brain scans show a salvageable area (penumbra) that is at least 15 ml and larger than the already damaged core.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a clot-busting medication (tenecteplase) intravenously before mechanical thrombectomy—a procedure to physically remove a large blood clot from the brain—improves recovery better than thrombectomy alone in patients with large ischemic strokes.
This trial tests if the clot-busting drug tenecteplase can help people with a moderate to severe stroke when given 24 to 72 hours after symptoms began. It aims to see if this later treatment window can improve recovery and reduce disability.
This study tests whether giving a clot-busting drug called tenecteplase directly into the brain's blood vessels can help complete the removal of a clot after a first attempt at mechanical extraction was only partially successful.
This trial tests a clot-dissolving drug called tenecteplase given 4.5 to 24 hours after a stroke caused by a blockage in a medium-sized brain artery. It aims to see if waiting longer than usual still helps reduce disability.
This trial tests a new clot-busting medicine called tenecteplase, given directly into the blood vessel in the brain, to treat strokes caused by a blockage in a medium-sized artery. The goal is to see if it can help restore blood flow and reduce disability, especially for patients who can be treated within 24 hours of stroke onset.
This trial tests if giving a second dose of the clot-busting drug tenecteplase can help people whose stroke symptoms don't improve after the first dose, when a large or medium artery in the brain is still blocked. It may be an option for patients who cannot have a mechanical clot removal procedure.
Hear when a new Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.